Jilin, China, May 23, 2025 — Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT), a Chinese veterinary vaccine company involved in the research, development, production, and sales of animal vaccines, particularly for livestock, announced that it received a notice from the NASDAQ Stock Market on May 20, 2025. The notice (the “Delinquency Letter”) stated the company was not in accordance with NASDAQ Listing Rule 5250(c)(1) because it failed to submit its Form 20-F annual report for the year ending December 31, 2024 (the “2024 Annual Report”) on time.

According to NASDAQ regulations, Zhengye Biotechnology has 60 calendar days from the date of the Delinquency Letter to present a plan to regain compliance (the “Compliance Plan”). If NASDAQ approves the Compliance Plan, the company may receive an extension of up to 180 days from the original Form 20-F deadline, or until November 11, 2025, to meet the requirements. Zhengye intends to submit its Compliance Plan within the given 60-day timeframe.

The Delinquency Letter does not currently affect the listing of Zhengye’s shares on the Nasdaq Capital Market.

This announcement fulfills the requirement of NASDAQ Listing Rule 5810(b) for prompt disclosure of deficiency notifications.

About Zhengye Biotechnology Holding Limited

Zhengye Biotechnology Holding Limited, through its operating entity Jilin Zhengye Biological Products Co., Ltd. in Jilin, China, focuses on researching, developing, manufacturing, and selling veterinary vaccines, especially for livestock. With over 20 years of experience, the operating entity aims to improve animal health, offering 44 veterinary vaccines for swine, cattle, goats, sheep, poultry, and dogs. These products are available in 28 Chinese provinces and are exported to Vietnam, Pakistan, and Egypt. The operating entity operates three GMP veterinary vaccine production facilities, including 13 GMP vaccine production lines, a quality examination center, and an animal facility for vaccine development. The operating entity employs 49 individuals with over a decade of experience in the veterinary vaccine industry. More information is available on the Company’s website: .

Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties. These statements are based on the Company’s expectations and projections regarding future events that may impact its financial condition, operating results, business strategy, and financial needs. These statements can be identified by terms such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” and similar expressions. The Company is not obligated to update or revise any forward-looking statements to reflect new events or changes in expectations, except as required by law. While the Company believes its expectations are reasonable, it cannot guarantee their accuracy and advises investors that actual results may differ significantly from anticipated results. Investors are encouraged to review other factors that may affect the Company’s future results in its registration statement and other SEC filings.

For more information, please contact:

Zhengye Biotechnology Holding Limited
Investor Relations Department
Email:

Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: